Selank: Anxiolytic Peptide Research, GABA Modulation & Immune Studies

Written by NorthPeptide Research Team

For laboratory and research use only. Not for human consumption.

What Is Selank?

Selank is a synthetic heptapeptide analog of the naturally occurring immunomodulatory peptide tuftsin. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro — consisting of the four-amino-acid tuftsin core (Thr-Lys-Pro-Arg) with a C-terminal Pro-Gly-Pro extension identical to the stability-enhancing modification used in Semax. This structural similarity is not coincidental: both peptides were developed at the Institute of Molecular Genetics of the Russian Academy of Sciences using the same design strategy of adding a Gly-Pro-rich extension to naturally occurring bioactive peptide fragments.

While Semax was designed as a nootropic based on the ACTH fragment, Selank was developed as an anxiolytic (anti-anxiety) agent based on tuftsin, a tetrapeptide produced by enzymatic cleavage of the heavy chain of immunoglobulin G (IgG). Tuftsin was originally characterized for its immunostimulatory properties — particularly its ability to enhance phagocytosis and natural killer cell activity — but the development of Selank revealed significant neurological effects that were not prominent features of the parent molecule.

Selank has been approved as a pharmaceutical product in Russia since 2009, where it is available as a 0.15% nasal spray indicated for generalized anxiety disorder (GAD) and neurasthenia. Its dual profile as both an anxiolytic and immunomodulatory agent is unusual in pharmacology and has generated research interest in conditions where anxiety and immune dysfunction co-occur.

How Selank Works: Mechanism of Action

Selank’s anxiolytic and immunomodulatory effects are mediated through several distinct but interconnected mechanisms:

• GABAergic system modulation — Selank has been shown to influence the gamma-aminobutyric acid (GABA) system, the brain’s primary inhibitory neurotransmitter network. Research has documented that Selank allosterically modulates GABA-A receptors, enhancing the inhibitory effects of endogenous GABA without directly activating the receptor. This mechanism is functionally similar to benzodiazepines, which also enhance GABAergic transmission, but Selank does not bind to the benzodiazepine site and does not produce the sedation, dependence, or cognitive impairment associated with benzodiazepine use.
• Enkephalin system modulation — Selank inhibits the enzymes that degrade enkephalins — the body’s endogenous opioid peptides involved in stress response, mood regulation, and pain modulation. By extending the half-life of enkephalins at the synapse, Selank may enhance the natural stress-buffering capacity of the endogenous opioid system. Specifically, Selank has been shown to inhibit enkephalin-degrading aminopeptidases, increasing leu-enkephalin and met-enkephalin levels in brain tissue.
• Serotonin metabolism — Research has documented that Selank influences serotonin (5-HT) metabolism in the brain, modulating both serotonin synthesis and turnover. Studies in rat brain tissue have reported changes in 5-HT and its metabolite 5-HIAA in the hypothalamus, hippocampus, and frontal cortex following Selank administration. These serotonergic effects are consistent with the peptide’s anxiolytic properties, as serotonin dysregulation is a well-established feature of anxiety disorders.
• BDNF and neurotrophic factor expression — Similar to Semax, Selank has been shown to upregulate brain-derived neurotrophic factor (BDNF) expression in the hippocampus, though the magnitude of this effect appears smaller than that observed with Semax. Selank also modulates NGF (nerve growth factor) expression, contributing to its neuroprotective profile.
• Gene expression modulation — Transcriptomic studies have revealed that Selank influences the expression of 36 genes in the hippocampus, with functional clusters related to GABAergic signaling, neurotransmitter transport, immune function, and apoptosis regulation. The pattern of gene expression changes is distinct from that produced by Semax, consistent with the different pharmacological profiles of the two peptides.
• Immune system modulation — Inherited from the parent tuftsin molecule, Selank retains significant immunomodulatory properties. Research has documented effects on T-helper cell balance (Th1/Th2 ratio), natural killer cell activity, interferon production, and inflammatory cytokine regulation. These immune effects are bidirectional — Selank appears to enhance immune responses that are suppressed and moderate responses that are excessive, consistent with immunomodulation rather than simple stimulation or suppression.

Anxiolytic Research

Preclinical Anxiety Models

Selank has been evaluated in multiple validated rodent models of anxiety:

• Elevated plus maze — Selank-treated animals showed increased time spent in the open arms (indicating reduced anxiety) comparable to diazepam, without the reduction in total arm entries (locomotor activity) typically seen with benzodiazepines
• Light-dark box — Increased exploration of the illuminated compartment, consistent with anxiolytic activity
• Vogel conflict test — Increased punished drinking behavior, a standard measure of anxiolytic efficacy that correlates well with clinical anti-anxiety effects
• Social interaction test — Enhanced social behavior in unfamiliar environments, suggesting reduced social anxiety

A key finding across these models was that Selank produced anxiolytic effects without sedation or motor impairment — a significant differentiator from benzodiazepines, which reliably reduce anxiety but also impair cognitive function and motor coordination.

Comparison with Benzodiazepines

The comparison between Selank and benzodiazepines is particularly relevant given the limitations of current anxiolytic pharmacotherapy:

Parameter	Selank	Benzodiazepines
Anxiolytic effect	Comparable in preclinical models	Well-established
Sedation	Not observed	Significant
Cognitive impairment	Not observed (may enhance cognition)	Significant (anterograde amnesia)
Motor impairment	Not observed	Significant (ataxia)
Tolerance development	Not documented	Develops within weeks
Physical dependence	Not documented	Significant risk
Withdrawal syndrome	Not documented	Potentially severe
GABA mechanism	Allosteric modulation (not benzo site)	Benzodiazepine site agonism

Russian Clinical Data

Clinical studies conducted for the Russian approval of Selank evaluated the peptide in patients diagnosed with generalized anxiety disorder. Reported findings include:

• Significant reductions in Hamilton Anxiety Rating Scale (HAM-A) scores compared to baseline
• Anxiolytic effects observed within the first week of treatment, with continued improvement over the 14-day treatment course
• No sedation, cognitive impairment, or withdrawal effects upon discontinuation
• Improvements in vegetative (autonomic) symptoms of anxiety, including palpitations, sweating, and gastrointestinal distress

Immune Function Research

Selank’s immunomodulatory properties, inherited from the tuftsin parent molecule but enhanced by the stability-conferring Pro-Gly-Pro extension, represent a unique feature among anxiolytic compounds.

Innate Immunity

• Phagocytosis enhancement — Selank, like tuftsin, stimulates phagocytic activity of monocytes, macrophages, and neutrophils. This effect is mediated through tuftsin receptor-dependent signaling.
• Natural killer cell activity — Research has documented enhanced NK cell cytotoxicity following Selank treatment, contributing to improved innate immune surveillance.
• Interferon modulation — Selank has been shown to influence interferon-gamma production, a key cytokine in antiviral and antitumor immunity.

Adaptive Immunity

• T-helper cell balance — Selank has demonstrated the ability to modulate the Th1/Th2 balance, shifting toward Th1 responses when Th2 predominance exists (as in allergic conditions) and vice versa. This bidirectional modulation is consistent with immune homeostasis restoration rather than unidirectional stimulation.
• Immunoglobulin production — Effects on IgA, IgG, and IgM production have been documented, with the direction of change depending on baseline immune status.

Psychoneuroimmunology Relevance

The dual anxiolytic-immunomodulatory profile of Selank is particularly relevant to the emerging field of psychoneuroimmunology (PNI), which studies the bidirectional relationships between psychological states, the nervous system, and immune function. Chronic anxiety and stress are well-documented causes of immune dysregulation, and an agent that simultaneously addresses both anxiety and immune function could have relevance in conditions where these systems interact — including chronic stress, autoimmune conditions with anxiety comorbidity, and immune dysfunction associated with psychological disorders.

Cognitive Research

While Selank’s primary characterization is as an anxiolytic, research has also documented nootropic effects, though these are generally considered secondary to those of Semax:

• Enhanced memory consolidation in passive avoidance paradigms
• Improved learning acquisition in water maze tasks, particularly under stress conditions where anxiety normally impairs performance
• BDNF and NGF upregulation in hippocampus (though to a lesser degree than Semax)
• Modulation of gene expression programs related to synaptic plasticity

The cognitive effects of Selank may be partly attributable to its anxiolytic properties — anxiety is a well-known impairment of cognitive function, and reducing anxiety can unmask underlying cognitive capacity. However, the direct neurotrophic factor modulation suggests additional cognitive mechanisms beyond anxiety reduction.

Neuroprotection Research

Selank has been investigated in models of neurological injury and neurodegeneration:

• Oxidative stress protection — Selank has demonstrated antioxidant properties in brain tissue, reducing markers of lipid peroxidation and enhancing endogenous antioxidant enzyme activity
• Anti-apoptotic effects — In models of neuronal injury, Selank has been associated with reduced caspase activation and decreased apoptotic cell death
• Alcohol neurotoxicity — Research has investigated Selank’s potential to attenuate ethanol-induced neurotoxicity, with studies reporting reduced neuronal damage in alcohol-exposed brain tissue

Dosing in Research Models

Research Context	Dose	Route	Duration
Russian clinical (anxiety)	75–450 μg/day	Intranasal	14-day courses
Rodent anxiety models	100–300 μg/kg	Intranasal or IP	7–14 days
Immune function studies	100–500 μg/kg	IP injection	5–14 days
Neuroprotection	100–300 μg/kg	IP injection	Single dose to 7 days
Gene expression studies	100 μg/kg	IP injection	Single dose (24h analysis)

Reconstitution and Handling

• Storage — Lyophilized Selank at -20°C for long-term stability
• Reconstitution — Reconstitute with sterile bacteriostatic water. For intranasal research protocols, prepare at 1.5–3 mg/mL.
• Stability — Reconstituted solution stable approximately 20–30 days at 2–8°C. The Pro-Gly-Pro extension provides significant resistance to enzymatic degradation.
• Intranasal delivery — As with Semax, intranasal administration provides direct CNS access via the olfactory pathway, bypassing the blood-brain barrier.

Safety Profile

Selank has an extensive safety record from both preclinical studies and clinical use in Russia since 2009:

• No sedation — Unlike benzodiazepines, Selank does not cause drowsiness or psychomotor impairment at anxiolytic doses
• No dependence or tolerance — Over a decade of clinical use has not revealed dependence liability or tolerance development
• No withdrawal syndrome — Discontinuation after chronic use does not produce rebound anxiety or withdrawal effects
• Minimal side effects — The most commonly reported effects are mild nasal irritation (from intranasal delivery) and occasional transient taste disturbance
• No hormonal effects — Despite its immunomodulatory properties, Selank does not cause significant changes in cortisol, thyroid hormones, or other endocrine parameters
• Safe immune modulation — The immunomodulatory effects are homeostatic rather than stimulatory, reducing the risk of immune overactivation

Current Limitations and Future Directions

• Russian-language literature — As with Semax, a significant portion of Selank clinical data is in Russian-language journals, limiting accessibility for international researchers
• No Western clinical trials — Selank has not been evaluated in FDA-standard randomized controlled trials
• Limited head-to-head comparisons — Direct comparisons with established anxiolytic agents (SSRIs, buspirone) in standardized human trials are not available
• Mechanism of GABA interaction — While Selank’s allosteric modulation of GABA-A receptors has been documented, the precise binding site and molecular mechanism are not fully characterized
• Combination research gap — Despite the complementary profiles of Selank and Semax, published combination studies are limited

Future research directions include Western-standard clinical trials for anxiety disorders, characterization of the GABA-A receptor interaction site, investigation of Selank in psychoneuroimmunology contexts, and expanded research on the Selank-Semax combination.

Summary

Selank is a synthetic tuftsin analog that functions as a non-sedating anxiolytic through GABAergic modulation, enkephalin system enhancement, and serotonergic signaling, while simultaneously exerting immunomodulatory effects inherited from the parent tuftsin molecule. Its unique dual anxiolytic-immunomodulatory profile, absence of sedation and dependence liability, and over a decade of clinical use in Russia distinguish it from conventional anxiolytic pharmacotherapy. The primary limitations are the absence of Western-standard clinical trials and the predominantly Russian-language evidence base. For researchers interested in anxiety, immune modulation, or the intersection of the two, Selank represents a well-characterized investigational compound with a distinctive mechanism of action.

View Selank in our research catalog. For complementary cognitive research, see Semax.

---

Summary of Key Research References

Study	Year	Type	Focus	Reference
Zozulya et al.	2016	In Vivo	Selank affects expression of genes involved in GABAergic neurotransmission	PMC4757669
Zozulya et al.	2017	In Vitro	GABA, Selank, and olanzapine affect GABAergic gene expression in IMR-32 cells	PMC5328971
Semenova et al.	2017	In Vivo	Selank enhances diazepam effect in reducing anxiety under chronic mild stress	PMC5322660
Kasian et al.	2018	Review	Peptide-based anxiolytics — molecular aspects of Selank biological activity	PMID 30255741
Medvedev et al.	2008	Clinical Trial	Efficacy of Selank in therapy of generalized anxiety disorders and neurasthenia	PMID 18454096
Ershov et al.	2009	In Vivo	Antiviral properties of structural fragments of Selank	PMID 20506839
Andreeva et al.	2020	In Vivo	Influence of Selank on cytokine levels under social stress conditions	PMID 32621722
Kozlovskaya et al.	2014	In Vivo	Efficacy of Selank during alcohol withdrawal syndrome in rats	PMID 24913576

This article is for informational and research purposes only. It does not constitute medical advice. All peptides sold by NorthPeptide are intended exclusively for laboratory and research use. Not for human consumption.